TY - JOUR
T1 - Determinants of influenza vaccine purchasing decision in the US
T2 - A conjoint analysis
AU - Pereira, Claudia C.A.
AU - Mulligan, Matthew
AU - Bridges, John F.P.
AU - Bishai, David
N1 - Funding Information:
The study was funded by a grant from Becton, Dickinson & Company . We would like to thank Steven Arenberg for his help with programming the web survey, and Samantha Vogt, MD, MPH, University of Pittsburgh. We also acknowledge the helpful comments received from Brian Lynch, Nuphar Rozen-Adler, Justin Wright, and Jennifer Zolot.
PY - 2011/2/4
Y1 - 2011/2/4
N2 - We explore the determinants of influenza vaccine purchasing decision in the US via a nationwide survey of 251 medical office managers and physicians on preferences for seven vaccine presentation attributes: price, presence of thimerosal, contamination risk, storage space requirement, number of preparation steps, dosing errors and speed. The findings show that thimerosal, contamination risk, and dosing errors were the most important attributes. For pediatricians, thimerosal's absence was shown to be the most valuable attribute. Participants would be willing to spend the following additional amounts per dose of influenza vaccine to acquire products as follows: $5.06 for the absence of thimerosal, $5.23 for a lower contamination risk, $4.94 for lower chance of dosing errors. They would pay $1.08 more for influenza vaccines that were faster to administer, $1.27 more for vaccines that were easier to store, and $1.76 more for vaccines that had fewer steps to administer.
AB - We explore the determinants of influenza vaccine purchasing decision in the US via a nationwide survey of 251 medical office managers and physicians on preferences for seven vaccine presentation attributes: price, presence of thimerosal, contamination risk, storage space requirement, number of preparation steps, dosing errors and speed. The findings show that thimerosal, contamination risk, and dosing errors were the most important attributes. For pediatricians, thimerosal's absence was shown to be the most valuable attribute. Participants would be willing to spend the following additional amounts per dose of influenza vaccine to acquire products as follows: $5.06 for the absence of thimerosal, $5.23 for a lower contamination risk, $4.94 for lower chance of dosing errors. They would pay $1.08 more for influenza vaccines that were faster to administer, $1.27 more for vaccines that were easier to store, and $1.76 more for vaccines that had fewer steps to administer.
KW - Clinician preferences
KW - Determinants of demand
KW - Economics
KW - Thimerosal
KW - Vaccine safety
UR - http://www.scopus.com/inward/record.url?scp=79151471161&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79151471161&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2010.12.027
DO - 10.1016/j.vaccine.2010.12.027
M3 - Article
C2 - 21185424
AN - SCOPUS:79151471161
SN - 0264-410X
VL - 29
SP - 1443
EP - 1447
JO - Vaccine
JF - Vaccine
IS - 7
ER -